Kroumpouzos George, Paroikaki Maria Eleni, Yumeen Sara, Bhargava Shashank, Mylonakis Eleftherios
Department of Dermatology, Warren Alpert Medical School at Brown University, Providence, RI 02903, USA.
Department of School of Medicine, Imperial College London, London SW7 2BX, UK.
Microorganisms. 2022 Mar 15;10(3):624. doi: 10.3390/microorganisms10030624.
Because of the increasing emergence of cutaneous reactions from COVID-19 vaccines worldwide, we investigated the published reports of these complications. We searched the PubMed, Google Scholar, and Scopus databases and the preprint server bioRxiv for articles on cutaneous complications linked to mRNA-1273 (Moderna), BNT162b2 (Pfizer-BioNTech), and AZD1222 (AstraZeneca-Oxford University) vaccines published until 30 September 2021. Eighty studies describing a total of 1415 reactions were included. Cutaneous reactions were more prevalent in females (81.6%). Delayed large local reactions were the most common complication (40.4%), followed by local injection site reactions (16.5%), zoster (9.5%), and urticarial eruptions (9.0%). Injection site and delayed large local reactions were predominantly caused by the mRNA-1273 vaccine (79.5% and 72.0%, respectively). BNT162b2 vaccination was more closely linked to distant reactions (50.1%) than mRNA-1273 (30.0%). Zoster was the most common distant reaction. Of reactions with adequate information for both vaccine doses, 58.3% occurred after the first dose only, 26.9% after the second dose only, and 14.8% after both doses. Overall, a large spectrum of cutaneous reaction patterns occurred following the COVID-19 vaccination. Most were mild and without long-term health implications. Therefore, the occurrence of such dermatologic complications does not contraindicate subsequent vaccination.
由于全球范围内新冠病毒疫苗皮肤反应的出现日益增多，我们对这些并发症的已发表报告进行了调查。我们在PubMed、谷歌学术和Scopus数据库以及预印本服务器bioRxiv中搜索了截至2021年9月30日发表的与mRNA-1273（Moderna）、BNT162b2（辉瑞-生物科技）和AZD1222（阿斯利康-牛津大学）疫苗相关的皮肤并发症文章。纳入了80项研究，共描述了1415例反应。皮肤反应在女性中更为普遍（81.6%）。延迟性大局部反应是最常见的并发症（40.4%），其次是局部注射部位反应（16.5%）、带状疱疹（9.5%）和荨麻疹疹（9.0%）。注射部位和延迟性大局部反应主要由mRNA-1273疫苗引起（分别为79.5%和72.0%）。与mRNA-1273（30.0%）相比，BNT162b2疫苗接种与远处反应（50.1%）的关联更为密切。带状疱疹是最常见的远处反应。在两种疫苗剂量信息充足的反应中，58.3%仅在第一剂后出现，26.9%仅在第二剂后出现，14.8%在两剂后出现。总体而言，新冠病毒疫苗接种后出现了广泛的皮肤反应模式。大多数反应轻微，对长期健康没有影响。因此，此类皮肤并发症的发生并不妨碍后续接种疫苗。
